Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Strengthening Security for Gene Synthesis: Recommendations for Governance.

Kobokovich A, West R, Montague M, Inglesby T, Gronvall GK.

Health Secur. 2019 Nov 22. doi: 10.1089/hs.2019.0110. [Epub ahead of print]

PMID:
31755783
2.

Clade X: A Pandemic Exercise.

Watson C, Toner ES, Shearer MP, Rivers C, Meyer D, Hurtado C, Watson M, Gronvall GK, Adalja AA, Sell TK, Inglesby T, Cicero A.

Health Secur. 2019 Sep/Oct;17(5):410-417. doi: 10.1089/hs.2019.0097.

PMID:
31593508
3.

Does Biotechnology Pose New Catastrophic Risks?

DiEuliis D, Ellington AD, Gronvall GK, Imperiale MJ.

Curr Top Microbiol Immunol. 2019;424:107-119. doi: 10.1007/82_2019_177.

PMID:
31463535
4.

Analysis of sectoral participation in the development of Joint External Evaluations.

McPhee E, Gronvall GK, Sell TK.

BMC Public Health. 2019 May 23;19(1):631. doi: 10.1186/s12889-019-6978-8.

5.

Recommendations on How to Manage Anticipated Communication Dilemmas Involving Medical Countermeasures in an Emergency.

Schoch-Spana M, Brunson E, Chandler H, Gronvall GK, Ravi S, Sell TK, Shearer MP.

Public Health Rep. 2018 Jul/Aug;133(4):366-378. doi: 10.1177/0033354918773069. Epub 2018 May 30.

6.

Erratum for DiEuliis and Gronvall, "A Holistic Assessment of the Risks and Benefits of the Synthesis of Horsepox Virus".

DiEuliis D, Gronvall GK.

mSphere. 2018 Apr 11;3(2). pii: e00160-18. doi: 10.1128/mSphere.00160-18. Print 2018 Apr 25. No abstract available.

7.

A Holistic Assessment of the Risks and Benefits of the Synthesis of Horsepox Virus.

DiEuliis D, Gronvall GK.

mSphere. 2018 Mar 7;3(2). pii: e00074-18. doi: 10.1128/mSphere.00074-18. eCollection 2018 Mar-Apr. Erratum in: mSphere. 2018 Apr 11;3(2):.

8.

Safety, security, and serving the public interest in synthetic biology.

Gronvall GK.

J Ind Microbiol Biotechnol. 2018 Jul;45(7):463-466. doi: 10.1007/s10295-018-2026-4. Epub 2018 Mar 21.

PMID:
29560534
9.

Options for Synthetic DNA Order Screening, Revisited.

DiEuliis D, Carter SR, Gronvall GK.

mSphere. 2017 Aug 23;2(4). pii: e00319-17. doi: 10.1128/mSphere.00319-17. eCollection 2017 Jul-Aug.

10.

Biodefense in the 21st century.

Gronvall GK.

Science. 2017 May 12;356(6338):588. doi: 10.1126/science.aan1118. No abstract available.

PMID:
28495718
11.

Expert Views on Biological Threat Characterization for the U.S. Government: A Delphi Study.

Watson CR, Watson MC, Ackerman G, Gronvall GK.

Risk Anal. 2017 Dec;37(12):2389-2404. doi: 10.1111/risa.12787. Epub 2017 Mar 17.

PMID:
28314075
12.

A Biosafety Agenda to Spur Biotechnology Development and Prevent Accidents.

Gronvall GK.

Health Secur. 2017 Jan/Feb;15(1):25-27. doi: 10.1089/hs.2016.0095. Epub 2017 Jan 16. No abstract available.

13.

Maintaining US Leadership in Emerging Biotechnologies to Grow the Economy of the Future.

Gronvall GK.

Health Secur. 2017 Jan/Feb;15(1):31-32. doi: 10.1089/hs.2016.0099. Epub 2017 Jan 16. No abstract available.

14.

Prevention of the Development or Use of Biological Weapons.

Gronvall GK.

Health Secur. 2017 Jan/Feb;15(1):36-37. doi: 10.1089/hs.2016.0096. Epub 2017 Jan 16. No abstract available.

15.

Singapore-Malaysia-Indonesia-US Dialogue on Biosecurity.

Gronvall GK, Ravi S, Inglesby T, Cicero A.

Health Secur. 2015 Nov-Dec;13(6):399-405. doi: 10.1089/hs.2015.0051. No abstract available.

PMID:
26690381
16.

US Competitiveness in Synthetic Biology.

Gronvall GK.

Health Secur. 2015 Nov-Dec;13(6):378-89. doi: 10.1089/hs.2015.0046.

17.

Addressing the Gap in International Norms for Biosafety.

Gronvall GK, Rozo M.

Trends Microbiol. 2015 Dec;23(12):743-744. doi: 10.1016/j.tim.2015.10.002. No abstract available.

PMID:
26654137
18.

Reply to "The 1977 H1N1 Influenza Virus Reemergence Demonstrated Gain-of-Function Hazards".

Rozo M, Gronvall GK.

MBio. 2015 Sep 29;6(5):e01524-15. doi: 10.1128/mBio.01524-15. No abstract available.

19.

BIOSECURITY. Assessing the bioweapons threat.

Boddie C, Watson M, Ackerman G, Gronvall GK.

Science. 2015 Aug 21;349(6250):792-3. doi: 10.1126/science.aab0713. No abstract available.

PMID:
26293941
20.

The Reemergent 1977 H1N1 Strain and the Gain-of-Function Debate.

Rozo M, Gronvall GK.

MBio. 2015 Aug 18;6(4). pii: e01013-15. doi: 10.1128/mBio.01013-15.

21.

Antimicrobial resistance is a global health emergency.

Toner E, Adalja A, Gronvall GK, Cicero A, Inglesby TV.

Health Secur. 2015 May-Jun;13(3):153-5. doi: 10.1089/hs.2014.0088. No abstract available.

22.

The existing guidance for "dual-use" research.

Gronvall GK.

Hastings Cent Rep. 2014 Nov-Dec;44(6 Spec no.):S34-5. doi: 10.1002/hast.396. No abstract available.

PMID:
25418701
23.

National-level biosafety norms needed for dual-use research.

Gronvall GK.

Front Public Health. 2014 Jul 14;2:84. doi: 10.3389/fpubh.2014.00084. eCollection 2014. No abstract available.

24.

U.S. medical countermeasure development since 2001: a long way yet to go.

Russell PK, Gronvall GK.

Biosecur Bioterror. 2012 Mar;10(1):66-76. doi: 10.1089/bsp.2012.0305. Review.

PMID:
22455680
25.

Everywhere you look: select agent pathogens.

Rambhia KJ, Ribner AS, Gronvall GK.

Biosecur Bioterror. 2011 Mar;9(1):69-71. doi: 10.1089/bsp.2011.0321. Epub 2011 Mar 1. No abstract available.

PMID:
21361793
26.

HHS guidance on synthetic DNA is the right step.

Gronvall GK.

Biosecur Bioterror. 2010 Dec;8(4):373-6. doi: 10.1089/bsp.2010.0127.

PMID:
21142764
27.

Prevention of biothreats: a look ahead.

Gronvall GK, Bouri N, Rambhia KJ, Franco C, Watson M.

Biosecur Bioterror. 2009 Dec;7(4):433-42. doi: 10.1089/bsp.2009.1112. No abstract available.

PMID:
20028252
28.

Antibiotic resistance.

Rambhia KJ, Gronvall GK.

Biosecur Bioterror. 2009 Dec;7(4):371-7. doi: 10.1089/bsp.2009.1105.

PMID:
20028245
29.

Influenza vaccine production for the U.S. market.

Smith LM, Gronvall GK.

Biosecur Bioterror. 2009 Sep;7(3):259-63. doi: 10.1089/bsp.2009.0921. No abstract available.

PMID:
19821749
30.

Preventing the development and use of biological weapons.

Gronvall GK.

Biosecur Bioterror. 2009 Mar;7(1):31-2. doi: 10.1089/bsp.2009.1003. No abstract available.

PMID:
19317619
31.

Developing medical countermeasures for biodefense.

Smith BT, Mair M, Gronvall GK, Matheny J.

Biosecur Bioterror. 2009 Mar;7(1):42-3. doi: 10.1089/bsp.2009.1008. No abstract available.

PMID:
19317614
32.

Biosafety laboratories.

Gronvall GK, Bouri N.

Biosecur Bioterror. 2008 Dec;6(4):299-307. doi: 10.1089/bsp.2008.1126. No abstract available.

PMID:
19117429
33.

Biodefense countermeasures: the impact of Title IV of the US Pandemic and All-Hazards Preparedness Act.

Gronvall G.

Emerg Health Threats J. 2008;1:e3. doi: 10.3134/ehtj.08.003. Epub 2008 Feb 29.

34.

The FDA animal efficacy rule and biodefense.

Gronvall GK, Trent D, Borio L, Brey R, Nagao L; Alliance for Biosecurity.

Nat Biotechnol. 2007 Oct;25(10):1084-7. No abstract available.

PMID:
17921984
35.

Flexible defenses roundtable meeting: promoting the strategic innovation of medical countermeasures.

Gronvall GK, Matheny J, Smith BT, Mair M, Chamberlain AT, Deitch S, Borio L, Inglesby TV, O'Toole T.

Biosecur Bioterror. 2007 Sep;5(3):271-7. No abstract available.

PMID:
17903096
36.

Immune-boosting adjuvants.

Chamberlain A, Gronvall GK.

Biosecur Bioterror. 2007 Sep;5(3):202-5. No abstract available.

PMID:
17903089
37.

Biomedical Advanced Research and Development Authority (BARDA) roundtable.

Gronvall GK, Smith BT, Matheny J, Mair M, Chamberlain A, Deitch S, Borio L, Inglesby TV, O'Toole T.

Biosecur Bioterror. 2007 Jun;5(2):174-9. No abstract available.

PMID:
17608604
38.

The science of biodefense: RNAi.

Chamberlain A, Gronvall GK.

Biosecur Bioterror. 2007 Jun;5(2):104-6. No abstract available.

PMID:
17608596
39.

High-containment biodefense research laboratories: meeting report and center recommendations.

Gronvall GK, Fitzgerald J, Chamberlain A, Inglesby TV, O'Toole T.

Biosecur Bioterror. 2007 Mar;5(1):75-85. No abstract available.

PMID:
17437355
40.

Getting medicine to millions: New strategies for mass distribution.

Lien O, Maldin B, Franco C, Gronvall GK.

Biosecur Bioterror. 2006;4(2):176-82.

PMID:
16792485
41.

Removing barriers to global pandemic influenza vaccination.

Gronvall GK, Borio LL.

Biosecur Bioterror. 2006;4(2):168-75.

PMID:
16792484
42.

The scientific response to a pandemic.

Gronvall GK, Waldhorn RE, Henderson DA.

PLoS Pathog. 2006 Feb;2(2):e9. No abstract available.

43.

Clustering class I MHC modulates sensitivity of T cell recognition.

Fooksman DR, Grönvall GK, Tang Q, Edidin M.

J Immunol. 2006 Jun 1;176(11):6673-80.

44.

Three-year program to discuss voluntary measures to strengthen the biological weapons convention concluded.

Grönvall GK, Franco C.

Biosecur Bioterror. 2006;4(1):13. No abstract available.

PMID:
16602144
45.

Bulls, Bears, and Birds: Preparing the Financial Industry for an Avian Influenza Pandemic.

Maldin B, Inglesby TV, Nuzzo JB, Lien O, Gronvall GK, Toner E, O'Toole T.

Biosecur Bioterror. 2005;3(4):363-7.

PMID:
16366846
46.

A new role for scientists in the Biological Weapons Convention.

Grönvall GK.

Nat Biotechnol. 2005 Oct;23(10):1213-6. No abstract available.

PMID:
16211054
47.

Navigating the storm: report and recommendations from the Atlantic Storm exercise.

Smith BT, Inglesby TV, Brimmer E, Borio L, Franco C, Gronvall GK, Kramer B, Maldin B, Nuzzo JB, Schuler A, Stern S, Henderson DA, Larsen RJ, Hamilton DS, O'Toole T.

Biosecur Bioterror. 2005;3(3):256-67.

PMID:
16181048
48.

Anthrax countermeasures: current status and future needs.

Borio LL, Gronvall GK.

Biosecur Bioterror. 2005;3(2):102-12.

PMID:
16000041

Supplemental Content

Loading ...
Support Center